The company became aware of NSE Circular No. NSE/CML/75748 dated 14th August 2026, which informed NSE members that Jenburkt Pharmaceuticals Limited's equity shares have been permitted to trade and admitted to dealings on the Capital Market Segment of NSE under the "Permitted to Trade" category. This admission became effective from 17th August 2026.
Key clarifications provided:
- The company has not applied for listing of its equity shares on NSE
- The equity shares continue to be listed on BSE Limited exclusively
- The availability for trading on NSE is solely under the "Permitted to Trade" category pursuant to the NSE circular
- Based on available records, no separate communication or intimation regarding this admission was received by the company from NSE
The disclosure is made for the information of the exchange, shareholders, and other stakeholders. The letter was digitally signed by Ashish R. Shah, Sr. VP and Company Secretary and Compliance Officer, on 22nd September 2026 at 12:59:50 IST.
Financial Impact
No financial impact quantified in the disclosure. The notification pertains to trading venue classification without affecting fundamental listing status or capital structure.